August 17, 2020 10:59 AM EDTUpdated 01:05 PM
R&D
FDA+

Ned Sharp­less' 'brain­child' nabs a speedy FDA re­view for small cell lung can­cer drug

Nicole DeFeudis

Editor

It was an­i­mal da­ta on G1 Ther­a­peu­tics’ on­col­o­gy drug tri­laci­clib that orig­i­nal­ly at­tract­ed cur­rent CEO Mark Vel­le­ca to the com­pa­ny six years ago. And now …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

Ex­clu­sive: In­sitro makes head­way on the hard­er road, dis­cov­er­ing new ALS drug tar­get

SiteOne Ther­a­peu­tics, a pain biotech that's part­nered with Ver­tex, nabs $100M

Au­ri­on’s eye cell ther­a­py im­proves vi­sion in small study, plots Phase 3 tri­al

In sur­prise move, FDA's No. 2 Bum­pus to leave agency at end of 2024

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

A service from the Financial Times